{"entity":{"id":"nct07716228","kind":"trial","name":"Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein","aka":["ADGP II"],"tldr":"A phase 3 trial of dexamethasone in pancreatic cancer, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, now recruiting.","summary":"Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein-bound is a phase 3, randomised interventional study registered as NCT07716228 by Second Affiliated Hospital, Zhejiang University, School of Medicine, with a registry enrolment figure of 74 participants, started 2025-12-12 and due to reach its primary completion in 2026-12-06. Interventions recorded: Auricular point stimulation plus dexamethasone; Standard pharmacologic antiemetic regimen. Conditions listed: Nausea and Vomiting Caused by Chemotherapy. Primary outcome: Proportion of patients experiencing nausea as assessed by NIC-CTC AE4.0. Pancreatic eligibility wording from the registry: \"* Patients must meet the following inclusion criteria for the study: \\* Age ≥ 18 years and ≤ 85 years; \\* Patients with pancreatic cancer after radical resection or with advanced pancreatic cancer, who require further chemotherapy with the gemcitabine plus paclitaxel albumin-bound regimen; \\* ECOG p\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07716228","url":"https://clinicaltrials.gov/study/NCT07716228"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":["dexamethasone"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07716228","phase":"3","setting":"Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein-bound in Pancreatic Cancer Treatment","sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","enrolled":74,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07716228/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"drug":[{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}